BAJAJ BROKING
Sun Pharma is set to acquire Checkpoint Therapeutics for up to $355 million. The deal includes an upfront payment of $4.10 per share, a 66% premium to Checkpoint’s last closing price. The acquisition strengthens Sun Pharma’s oncology segment, adding FDA-approved Unloxcyt to its portfolio.
Mumbai-based Sun Pharmaceutical Industries has finalised an agreement to acquire Checkpoint Therapeutics Inc. for up to $355 million (₹3,088 crore). This marks Sun Pharma’s second significant acquisition in two years, following its $576 million takeover of Concert Pharmaceuticals in 2023. The transaction is expected to close in the second quarter of 2025, pending regulatory approvals.
Also Read: Bharat Electronics Secures ₹843 Crore in New Defence Orders
Deal value: Sun Pharma will pay up to $355 million for Checkpoint Therapeutics.
Upfront payment: Shareholders will receive $4.10 per share, a 66% premium to Checkpoint’s closing price on 7 March 2025.
Contingent value rights: Additional payments of up to $0.70 per share depend on European regulatory approvals.
Strategic expansion: Sun Pharma strengthens its oncology portfolio, integrating Checkpoint’s FDA-approved Unloxcyt (cosibelimab-ipdl).
Financial performance: Checkpoint reported a $27.3 million net loss for the nine-month period ending September 2024.
Also Read: Aditya Birla Capital Infuses ₹300 Crore into Housing Finance Subsidiary via Rights Issue
Sun Pharma will acquire all outstanding shares of Checkpoint Therapeutics. Shareholders will receive $4.10 per share in cash, and an additional $0.70 per share if cosibelimab secures approval in key European markets.
Checkpoint Therapeutics, a Nasdaq-listed firm, is a commercial-stage immunotherapy company. Its lead product, Unloxcyt, is FDA-approved for cutaneous squamous cell carcinoma (cSCC). Despite this approval, Checkpoint faced financial struggles, with $0.04 million revenue and a $27.3 million net loss in the nine-month period ending September 2024.
Metric | Value (as of September 2024) |
Revenue | $0.04 million |
Net loss | $27.3 million |
Research and development expense | $19.3 million |
Cash balance | $4.7 million |
Accounts payable and accrued expenses | $15.6 million |
Checkpoint’s controlling stockholder, Fortress Biotech, has agreed to vote in favour of the acquisition. Fortress will also receive royalty payments from cosibelimab’s future sales.
The acquisition bolsters Sun Pharma’s presence in the oncology segment, reinforcing its strategy of expanding innovative treatments. Unloxcyt’s integration into Sun Pharma’s global portfolio is expected to strengthen its market positioning in the US, Europe, and other key regions.
Checkpoint’s board of directors formed a special committee to evaluate strategic options. After assessing multiple offers, the committee approved Sun Pharma’s proposal as the best risk-adjusted value for stockholders.
With this acquisition, Sun Pharma continues its global expansion in oncology-focused treatments. By adding Checkpoint’s FDA-approved Unloxcyt, Sun Pharma is expected to enhance its oncology business and further increase Sun Pharma share price. The acquisition, if successful, will contribute to Sun Pharma’s revenue while strengthening its oncology research capabilities. Investors will now monitor Sun Pharma share price closely as the deal progresses through regulatory approvals.
Also read: Syngene International to Invest $56 Million in US Subsidiary Expansion
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading